Publications by authors named "H Jochem van Ommen"
Background: Second primary malignancies (SPMs) are a well-known, long-term complication of antineoplastic treatment. This nationwide cohort study examined the risk of non-myeloid SPMs in survivors of adult acute myeloid leukaemia (AML) treated with intensive chemotherapy and, in some cases, allogeneic stem cell transplantation (alloSCT), compared to a matched general population.
Methods: Patients with incident AML between 2000 and 2018, alive and aged 18-70 years two years after start of intensive chemotherapy, were included and matched 1:10 to comparators from the general Danish population on sex, age, and the Nordic Multimorbidity Index.
Background: Arterial thrombosis is increasingly recognized in children and is most commonly related to the presence of an arterial catheter. Diagnosis and treatment of arterial thrombosis in children varies widely and consists of commonly available anticoagulants and antiplatelet drugs. No evidence-based guidelines exist for management strategies for catheter-related arterial thrombosis (CAT).
View Article and Find Full Text PDFBackground: Postthrombotic syndrome (PTS) is a chronic condition following deep vein thrombosis (DVT) and is associated with pain, swelling, and restricted use of the affected limb. In pediatric age groups, its incidence and risk factors are not well-known.
Methods: This observational cohort study of all consecutive children (≤18 years) with DVT treated at the Emma Children's Hospital Amsterdam between January 2001 and January 2021 was conducted to identify incidence and risk factors for PTS in neonates aged ≤2 months and children aged >2 months.
Article Synopsis
- NPM1-mutated acute myeloid leukemia (AML) has a generally good prognosis, but many patients still relapse, and traditional risk factors only include FLT3-ITD mutations and adverse karyotypes due to inconsistent findings from other factors.* -
- A study involving 1,357 patients revealed that specific mutations (FLT3-ITD, DNMT3A, WT1, and certain NPM1 mutations) correlate with poorer overall survival and are linked to measurable residual disease (MRD) status.* -
- Intensified chemotherapy using the FLAG-Ida regimen showed better outcomes across all patient subgroups, with particularly notable improvements for those in high-risk molecular categories.*